At present, the most common products in the mRNA drug market are delivery systems represented by LNP (Lipid Nano Particle), such as the Pfizer/BioNTech and Modena new crown mRNA vaccines that are now on the market.

Hui Therapy’s unique Cell Like System (CLS) delivery technology, whose structure is derived from the design of the protein-phospholipid layer in the biomimetic cell membrane, is a unique platform technology with independent intellectual property rights. It is especially suitable for targeted delivery of mRNA drugs.